SEC Company Response from NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545) (SDEV) — Sep 11, 2019
NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545)
Date: Sept. 11, 2019 · CIK: 0001389545 · Accession: 0001437749-19-018175
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-233623
Letter
Re:
nby20190910_corresp.htm
September 11, 2019
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
NovaBay Pharmaceuticals, Inc. (the “Company”)
Form S-3, File No. 333-233623
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective as of 5:00 p.m. (Eastern time) on Thursday, September 12, 2019, or as soon as practicable thereafter.
Very truly yours,
NovaBay Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm nby20190910_corresp.htm September 11, 2019 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: NovaBay Pharmaceuticals, Inc. (the “Company”) Form S-3, File No. 333-233623 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective as of 5:00 p.m. (Eastern time) on Thursday, September 12, 2019, or as soon as practicable thereafter. Very truly yours, NovaBay Pharmaceuticals, Inc. By: /s/ Justin Hall Justin Hall President & Chief Executive Officer and General Counsel cc: Abby E. Brown, Squire Patton Boggs (US) LLP